Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276486 | 0.77 | RORC (0.33) | POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL2268370 | 0.74 | ELANE (0.46) | — | |
| SCHEMBL19752991 | 0.66 | CFTR (0.52) | KDM4ENPC1HPGDRAB9A | |
| SCHEMBL28980546 | 0.66 | GPR183 (0.57) | LMNATP53POLBGPR183KDM4E | |
| SCHEMBL28980515 | 0.64 | GPR183 (0.55) | LMNATP53POLBGPR183HPGD | |
| SCHEMBL14484813 | 0.63 | NPC1 (0.44) | KDM4ENPC1HPGDRAB9AEDNRA | |
| SCHEMBL19415255 | 0.63 | LMNA (0.46) | SLC6A4SLC6A3SLC6A2LMNAPOLB | |
| SCHEMBL14458379 | 0.62 | CFTR (0.53) | SLC6A4SLC6A3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10165387 | 0.62 | CFTR (0.50) | SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL15256548 | 0.62 | CFTR (0.47) | SLC6A4SLC6A3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | SLC6A4 2931/4885SLC6A3 2983/4885SLC6A2 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.